论文部分内容阅读
目的检测骨桥蛋白(Osteopontin、OPN)与C-erbB-2、P53在乳腺癌组织中的表达情况,探讨其表达与乳腺癌临床病理特征的关系。方法采用S-P免疫组织化学技术检测OPN、C-erbB-2、P53蛋白在乳腺癌组织中的表达。结果50例乳腺癌组织中OPN、C-erbB-2、P53蛋白阳性表达率分别为76.0%,62.0%、56%。OPN蛋白表达在肿瘤大小、腋窝淋巴结转移及临床分期患者间差异均有统计学意义(P<0.05);C-erbB-2和P53蛋白表达在肿瘤大小、腋窝淋巴结转移、临床分期及不同ER、PR表达情况的患者间差异均有统计学意义(P<0.05)。OPN蛋白表达与C-erbB-2、P53蛋白表达有显著相关性(r=0.332,P=0.019;r=0.351,P=0.012)。结论OPN、C-erbB-2、P53蛋白与乳腺癌的临床病理特征密切相关,联合检测对乳腺癌患者病情评估、预测预后及临床用药具有重要的意义。
Objective To detect the expression of osteopontin (OPN), C-erbB-2 and P53 in breast cancer tissues and to investigate their relationship with the clinicopathological features of breast cancer. Methods S-P immunohistochemistry was used to detect the expression of OPN, C-erbB-2 and P53 in breast cancer tissues. Results The positive rates of OPN, C-erbB-2 and P53 in 50 cases of breast cancer were 76.0%, 62.0% and 56% respectively. There were significant differences in the expression of OPN protein between tumor size, axillary lymph node metastasis and clinical stage (P <0.05). The expressions of C-erbB-2 and P53 in tumor size, axillary lymph node metastasis, clinical stage and different ER, There was significant difference between patients with PR expression (P <0.05). The expression of OPN protein was positively correlated with the expression of C-erbB-2 and P53 (r = 0.332, P = 0.019; r = 0.351, P = 0.012). Conclusion The expressions of OPN, C-erbB-2 and P53 proteins are closely related to the clinicopathological features of breast cancer. The combined detection of them is of great significance for the assessment of disease, prognosis and clinical application in patients with breast cancer.